QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Romosozumab Biology, Fracture Prevention, Cardiovascular Safety and Pharmacovigilance

Test your understanding of the concepts covered by Romosozumab: Sclerostin–Wnt Biology, Bone Formation, Fracture Prevention, Cardiovascular Safety and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What was the most appropriate interpretation of FRAME’s fracture findings?

Romosozumab produced an early reduction in radiographic vertebral fractures compared with placebo, but the subsequent denosumab phase means the study evaluated a treatment sequence FRAME proved that romosozumab prevents all nonvertebral fractures in every treated patient FRAME showed that romosozumab is superior to alendronate because alendronate was the active comparator FRAME demonstrated that the effect continues indefinitely without maintenance therapy

Question 2 of 10 Which statement correctly interprets the EU RMP classification of a safety concern?

An important identified risk is necessarily the most frequent adverse reaction An important potential risk has already been proven causal in every patient RMP categories describe the regulator’s safety-planning framework and are not frequency rankings A risk absent from the RMP cannot be reported as an adverse event

Question 3 of 10 What is the most accurate sequence of events in canonical Wnt signalling relevant to bone formation?

Wnt binds Frizzled and LRP5/6, beta-catenin degradation is restrained, and beta-catenin supports transcriptional programmes favouring osteoblast activity Wnt binds RANKL, activates osteoclasts, and indirectly increases osteoblast differentiation Sclerostin binds Frizzled, stabilises beta-catenin, and increases bone formation Wnt enters the nucleus directly and replaces the need for a cell-surface receptor

Question 4 of 10 Why is the phrase “antagonist of an antagonist” appropriate for romosozumab?

The antibody blocks a receptor that normally suppresses sclerostin The antibody inhibits an endogenous inhibitor of a bone-forming signalling pathway The antibody simultaneously activates two unrelated receptors The antibody converts osteoclasts into osteoblasts

Question 5 of 10 A patient completes the 12 monthly romosozumab injections but has no antiresorptive appointment arranged. What is the principal pharmacovigilance and clinical concern?

The antibody will immediately convert into an osteoclast activator The absence of planned follow-on therapy may allow turnover to resume and cause loss of skeletal gains The patient will necessarily develop myocardial infarction The patient will no longer absorb calcium from the intestine

Question 6 of 10 Which statement about anti-romosozumab antibodies is most appropriate?

Their detection automatically proves reduced efficacy Their detection automatically proves a serious hypersensitivity reaction Their clinical relevance depends on assay characteristics, timing, titre, neutralising capacity and clinical context They cannot occur because romosozumab is humanised

Question 7 of 10 Which baseline finding should be addressed before initiating romosozumab because it directly increases the risk of treatment-related hypocalcaemia?

Corrected hypocalcaemia or inadequate calcium and vitamin D status A history of a healed vertebral fracture A prior response to exercise therapy A stable T-score documented at two skeletal sites

Question 8 of 10 Which regulatory-source pairing is most appropriate when verifying current EU contraindications, warnings and administration requirements?

The current EMA EPAR and Product Information A historical spontaneous-reporting database summary alone A single observational study abstract alone A general patient forum without jurisdictional information

Question 9 of 10 Which approach best reflects appropriate pharmacovigilance assessment of a suspected osteonecrosis of the jaw case?

Attribute any jaw pain automatically to romosozumab Collect evidence of persistent exposed or fistula-accessible bone, dental procedures, infection, imaging and relevant prior medicines and comorbidities Exclude the event if the patient has never received a bisphosphonate Classify the event solely from the anatomical location without clinical or radiological information

Question 10 of 10 What is the principal clinical implication of a recent fragility fracture in treatment selection?

It proves that the patient has adequate bone strength It signals increased imminent risk of another fracture and may support early use of a bone-forming strategy in an appropriate patient It excludes the possibility of vertebral fractures being clinically silent It means that calcium and vitamin D alone are sufficient treatment

QPPV.com

Knowledge Assessment: Romosozumab Biology, Fracture Prevention, Cardiovascular Safety and Pharmacovigilance

Cookie Settings